Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 07/30/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement, as a result of the closing bid price of its common stock having been at or above the minimum requirement of $1.00 per share for at least 10 consecutive trading days. As a result, Peregrine's shares of common stock will continue to trade on the NASDAQ capital market.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and infectious diseases. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .





Contact
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 30.07.2012 - 16:42 Uhr
Sprache: Deutsch
News-ID 169862
Anzahl Zeichen: 0

contact information:
Town:

TUSTIN, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 299 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement"
steht unter der journalistisch-redaktionellen Verantwortung von

Peregrine Pharmaceuticals (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Ant ...

TUSTIN, CA -- (Marketwired) -- 02/09/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 anti ...

Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combina ...

TUSTIN, CA -- (Marketwired) -- 01/16/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigation ...

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Imm ...

TUSTIN, CA -- (Marketwired) -- 12/12/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressi ...

Alle Meldungen von Peregrine Pharmaceuticals